Press Release

Naveris Announces New Data at EUROGIN International Multidisciplinary HPV Congress 2024

Naveris Unveils NAVigate-HPV: A Groundbreaking Registry to Advance HPV-Driven Cancer Diagnosis and Treatment

Naveris Announces New Data at ASTRO Multidisciplinary Head and Neck Cancers Symposium 2024

Naveris Announces Commercial Payor Coverage for NavDx® Test from Highmark, Inc.

Naveris Receives Medicare Coverage for NavDx® Test

Naveris Announces Two Peer-Review Publications Validating NavDx® Performance in Daily Clinical Practice

Naveris Announces New Data Featuring NavDx® in Oral Highlight and Poster Presentations at Upcoming ASTRO and AAO-HNSF 2023 Meetings

Mayo Clinic Collaborates with Naveris to Advance Precision Medicine in HPV-driven Head and Neck Cancer with NavDx in DART 2.0 Clinical Trial

Naveris Collaborators Present Award-winning Abstract at ASTRO 2022 on Potential of NavDx to Inform Treatment Strategies in HPV-driven Cancers

Naveris, Inc. Raises $51 Million to Advance Commercialization of NavDx